Asha Rizor, a graduate learner in the Pharmaceutical Sciences, recently co-hosted an American College of Toxicology podcast with the FDA. The episode, entitled “FDA Expedited Programs,” explores the process by which the FDA can expedite the review and approval of new drugs and vaccines in public health emergencies.
ToxChats is the official podcast of the American College of Toxicology, a national scientific organization dedicated to applied toxicology and related disciplines. Ms. Rizor is the youngest member and only HBCU learner on the national podcast committee.
Asha, an American College of Toxicology Graduate Fellow, is grateful to have had the opportunity to share her science on such a large platform. “It’s an honor to have participated. Scientific communication from trusted sources can help bridge the gap between communities and medical professionals, and I hope to have contributed to this through the podcast episode,” she said.
Asha is a PhD Candidate in Pharmacology/Toxicology in the laboratory of Dr. Eunsook Lee, Professor of Pharmaceutical Sciences. Her research explores the mechanisms of manganese-induced neurotoxicity.
The FDA is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and ensuring the safety of our nation’s food supply, cosmetics, and products that emit radiation.
To expedite the evaluation of new drugs and review marketing applications for drugs addressing unmet medical needs for patients with serious or life-threatening conditions, the FDA has established four expedited programs: Fast Track Designation, Breakthrough Therapy Designation, Priority Review, and Accelerated Approval. This episode examines FDA Expedited Programs with CDER’s Senior Regulatory Expedited Programs Manager, Miranda Raggio.
Listen to Podcast here: https://podcasts.apple.com/us/podcast/expedited-fda-programs/id1386379235?i=1000525890125